

Serving the growing biotechnology community

BioAgilytix Labs, LLC, a leading global contract research organization focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, continues to grow its footprint both organically and through acquisitions. Jim Datin, their President and CEO, explains why the recent addition of MicroConstants and Australia-based 360biolabs® to its family of companies fits in with their mission to serve as a one-stop bioanalysis partner to customers worldwide.

Founded in 2008 as a bioanalytics lab in Durham, North Carolina, BioAgilytix today is a leading global contract research organization focused on supporting pharmaceutical and biotech partners across all phases of drug development. With locations in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Hamburg, Germany and coming soon to Melbourne Australia, the company provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. “Our key strengths and differentiators remain Biology, Agility and Analytics,” says Mr. Datin, who joined the company in 2013, bringing to the table many years of experience in the Pharmaceutical, Life Sciences and Biotech industries. Over the course of his 25+ year career, he has been a successful CEO, director, and executive

in companies throughout the United States, Europe, and Asia. He is confident about the growth potential for BioAgilytix. “Our trusted scientific office, clinical expertise and deep bench of tenured experts keep a laser focus on quality, enabling our teams to deliver valuable scientific data on time, the first time. We remain as motivated as ever to helping customers get their beneficial therapeutics to patients faster.”

In November 2018, BioAgilytix was purchased by the private-equity firms of Copeba and GHO Capital. By then, BioAgilytix had already grown to become a recognized global leader in large molecule bioanalysis. The new ownership provided increased funding and resources to meet growing demand for its high-quality services, driven by its strong scientific reputation and leading expertise in biologics development. The company has since not only expanded and enhanced its own facilities, but also

acquired Cambridge Biomedical in 2019, and MicroConstants and 360biolabs® in 2021.

“Our growth, whether organically or via disciplined, aligned acquisitions, is all focused on providing our customers with a wider, expanded menu of services and capacity to help get their therapeutics to patients, faster,” explains Mr. Datin. “Our recent acquisition activities enable us to quickly expand our capacity and footprint into important geographic hubs where our client base is located. And by expanding our expertise and services into new areas such as small molecules, virology testing and other platforms, we’ve evolved into a one-stop bioanalysis partner.”

MicroConstants, known moving forward as BioAgilytix San Diego, is the largest bioanalytical LC/MS/MS lab on the US West Coast at 34,000 sq. ft. (3,000 m²). With its location in close proximity to high-value pharmaceutical and biotech marketplaces, BioAgilytix San Diego focuses on regulated bioanalysis and DMPK for small and large molecule therapeutics. It serves clients across the pharmaceutical and biotech industry and has deep expertise in bioanalytical testing services with over 20+ years of experience performing GLP compliant bioanalytical services. The business will complement BioAgilytix’s already impressive contract research services for the pharmaceutical and biotech industry, as Mr. Datin explains. “We believe that by joining forces, BioAgilytix and MicroConstants will not only create significant scientific and operational synergies, but also better serve the growing biotechnology community on the West Coast. Most importantly, our customers and their patients will benefit from the leading-





edge science the combined company will bring to market.”

360biolabs® is Australia’s most comprehensive specialty laboratory services organization for therapeutic, vaccine and diagnostics development. Located in Melbourne’s biomedical and clinical research hub, it offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC/MS/MS capabilities.

Melbourne, Australia is an important Asian biotech hub, and the acquisition of 360biolabs will enable BioAgilytix to be a part of the continued growth of this region. “Our existing network will gain access to 360biolabs services to expand our offerings to current BioAgilytix clients and we will leverage our global network of labs to support growth in the region. Plus, with the addition of the BSL-3 facility in Melbourne, we will be able to conduct a wider array of vaccine and anti-viral work within our existing BioAgilytix network,” says Mr. Datin.

BioAgilytix has begun integrating its new colleagues from MicroConstants and expects the acquisition to bring immediate customer benefits. “For 360biolabs, any integration activities must await Australian government FIRB approval, expected later this year,” Mr. Datin points out. “Due to the unique brand equity that the company enjoys in the region, it will be known moving

forward as 360biolabs, a BioAgilytix company.”

In closing, via both organic growth and aligned acquisitions, BioAgilytix continues its growth trajectory and evolution into a leading global contract research organization. “We are proud to offer customers an end-to-end and comprehensive portfolio of laboratory services located in key geographies around the world, all while continuing to maintain top client satisfaction scores and enviable employee retention rates,” Mr. Datin concludes.

The company’s evolution hasn’t gone unnoticed: BioAgilytix was recently ranked number 1939 on Inc.’s annual Inc.

5000 list, the most prestigious ranking of America’s fastest-growing private companies that achieved significant percentage growth of annual revenue over the three previous years. 2021 marks BioAgilytix’s eighth appearance on the list since 2013. 2021 reflects continued ranking improvement, as the most recent two years ranked BioAgilytix at #2951 (2020) and #1968 (2019).

BioAgilytix 

BioAgilytix
2300 Englert Drive
Durham, North Carolina 27713
USA
Website: www.bioagilytix.com
info@bioagilytix.com

